| RRC ID |
43906
|
| 著者 |
Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K.
|
| タイトル |
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
|
| ジャーナル |
Hum Pathol
|
| Abstract |
Somatic mutations of PIK3CA (phosphoinositide-3-kinase) have recently been shown playing an important role in the pathogenesis of ovarian clear cell carcinoma. In this study, the frequency of PIK3CA mutations and the relationship of PIK3CA mutations with clinicopathologic and biological variables were investigated in ovarian clear cell carcinomas from Japanese patients. Mutational analysis of PIK3CA was performed in 56 primary ovarian clear cell carcinomas from Japanese women. The relationship of these mutations with various clinicopathologic and biological variables (phosphorylated AKT and phosphorylated mTOR (mammalian target of rapamycin) expression by immunohistochemistry) was determined. To clarify the roles of PI3K/AKT activation in ovarian clear cell carcinomas harboring PIK3CA mutations, we inactivated the PI3K/AKT/mTOR pathway in ovarian carcinoma cells with LY294002, temsirolimus and NVP-BEZ235. Missense mutations of PIK3CA were found in 16 (28.6%) of 56 ovarian clear cell carcinomas, but no mutation was found in 15 ovarian high-grade serous carcinomas. PIK3CA mutations were significantly associated with a favorable overall survival of patients with ovarian clear cell carcinoma (P < .05). There was no significant association between PIK3CA mutations and phosphorylated AKT or phosphorylated mTOR immunointensity status. No relationship was found between PIK3CA mutation status and sensitivity to PI3K/AKT/mTOR inhibitors in ovarian clear cell carcinoma cells. No association of PIK3CA mutations was found between positive phosphorylated AKT and positive phosphorylated mTOR, which suggests that the PI3K/AKT/mTOR pathway may be activated by other molecular mechanisms. Although PIK3CA mutations were associated with a more favorable prognosis, they did not predict the sensitivity of ovarian clear cell carcinoma cells to PI3K/AKT/mTOR inhibitors.
|
| 巻・号 |
43(12)
|
| ページ |
2197-206
|
| 公開日 |
2012-12-1
|
| DOI |
10.1016/j.humpath.2012.03.011
|
| PII |
S0046-8177(12)00091-3
|
| PMID |
22705003
|
| MeSH |
Adenocarcinoma, Clear Cell / genetics*
Adenocarcinoma, Clear Cell / mortality
Adenocarcinoma, Clear Cell / pathology
Adult
Aged, 80 and over
Cell Line, Tumor
Class I Phosphatidylinositol 3-Kinases
Female
Humans
Middle Aged
Mutation*
Ovarian Neoplasms / genetics*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Phosphatidylinositol 3-Kinases / genetics*
Phosphatidylinositol 3-Kinases / metabolism
Phosphorylation
Prognosis
Proto-Oncogene Proteins c-akt / metabolism
TOR Serine-Threonine Kinases / metabolism
|
| IF |
2.735
|
| 引用数 |
42
|
|
WOS 分野
|
PATHOLOGY
|
| リソース情報 |
| ヒト・動物細胞 |
JHOC-9(RCB2226)
JHOC-5(RCB1520) |
